Artiva Biotherapeutics (ARTV) Accumulated Depreciation (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Accumulated Depreciation data on file, last reported at $9.1 million in Q1 2026.

• On a quarterly basis, Accumulated Depreciation rose 39.36% year-over-year to $9.1 million in Q1 2026; TTM through Mar 2026 was $9.1 million, a 39.36% increase from a year earlier, with the FY2025 full-year figure at $8.5 million, up 42.78% from the prior year.
• Accumulated Depreciation for Q1 2026 stood at $9.1 million, up from $8.5 million in the prior quarter.
• Over the last five years, Accumulated Depreciation for ARTV reached as high as $9.1 million in Q1 2026 and fell as low as $3.5 million in Q4 2023.
• Historically, Accumulated Depreciation has averaged $6.7 million across 4 years, with a median of $6.8 million in 2025.
• Across the five-year window, Accumulated Depreciation jumped 67.7% in 2024 and surged 39.36% in 2026, its largest moves.
• Year by year, Accumulated Depreciation stood at $3.5 million in 2023, then soared by 67.7% to $5.9 million in 2024, then surged by 42.78% to $8.5 million in 2025, then grew by 7.67% to $9.1 million in 2026.
• Per Business Quant data, the three most recent Accumulated Depreciation figures were $9.1 million in Q1 2026, $8.5 million in Q4 2025, and $7.8 million in Q3 2025.